GeneDx Expects 2024 Revenues Of $284M-$290M Versus Prior Guidance Of $255M-$265M Consensus Of $263.37M
Portfolio Pulse from Benzinga Newsdesk
GeneDx has raised its 2024 revenue guidance to $284M-$290M, up from $255M-$265M, surpassing the consensus of $263.37M. The company also expects to improve its adjusted gross margin to at least 62% and reduce net cash usage to $60M-$65M.
October 29, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeneDx has increased its 2024 revenue guidance to $284M-$290M, exceeding previous estimates and consensus. The company also anticipates improved gross margins and reduced cash usage.
GeneDx's updated guidance indicates stronger than expected financial performance, with increased revenue projections and improved margins. This positive outlook is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100